PRME Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 21.98%, SMA50 16.26%, SMA200 17.84%). The stock’s 14-day RSI is 65.75 (firm momentum), while the ATR of 0.3 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -36.89% below its high and over 294.59% above its low. Average 10-day trading volume of 2.83 million shares is slightly above the 3-month average of 2.48 million, indicating heightened recent market interest.

Prime Medicine, Inc. generated EPS of -$1.48 over the past year. Five-year average earnings growth is -124.13%. Wall Street analysts project EPS growth of 20.13% annually over the next five years. The latest quarter delivered EPS of -$0.28. The next quarter is forecast at -$0.25. Next year's EPS is expected at $5.24. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 3 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $4.25. The high target offers 283.39% upside. The low target suggests 35.78% downside. The mean target is $8.71. This offers 178.27% upside. Prime Medicine, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 16.67%. The prior quarter beat by -12.0%. Over the last six quarters, Apple has recorded several small beats. These include -16.22% in February 28, 2025.

Prime Medicine, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.45. This means the shares are trading below this model’s fair value.

Prime Medicine, Inc. has 178.27 million shares outstanding. The public float is 58.40 million shares, elevated short interest at 16.94% of float. This equals 18.37 million shares. The short ratio is 3.98 days. Institutional investors hold 84.57% of the float. Insiders own 23.77%. Liu David R. holds 20.24 million shares, ARCH Venture Partners X, LLC has 6.23 million shares and ARCH Venture Partners XII, LLC has 6.23 million shares.

Prime Medicine, Inc. (NASDAQ:PRME) closed at $3.13 USD, losing -$0.14 (-4.28%) from the previous close of $3.27. The stock is currently mid-range between its 52-week high and low $1.11 and $6.94. With a market capitalization of about $565.33 million, Prime Medicine, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.36). Key stats such as the average daily volume over the past year has been around 2.45 million shares, in line with its 52-week average. Headquartered in Cambridge, MA, Prime Medicine, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Allan Reine, the company employs approximately 214 people and listed since October 20, 2022. Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology.

Prime Medicine, Inc. trades at a P/E ratio of -2.79, slightly below the S&P 500 average, with a price-to-sales ratio of 139.92 and a price-to-book ratio of 7.22 trading at moderately above to book value. The P/FCF stands at -3.56, also below market averages.

Our AI price prediction model suggests that Prime Medicine, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.27%, with price expected at $2.84 by May 28, 2026, within a range of $2.68 to $3.02 3-Month Outlook: Projected rise of 292.65%, reaching $12.29 by August 12, 2026, with a range of $12.14 to $12.48. 1-Year Outlook: Projected gain of 116.93%, with price at $6.79 by May 14, 2027, within a range of $0.47 to $7.80.

Prime Medicine, Inc. (NASDAQ:PRME) shares are up 12.1% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Prime Medicine, Inc. trading at a premium to the broader market with a P/E of -2.79. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $14.25, suggesting 355.27% upside. Our AI forecast model points to short-term weakness (-9.27% over two weeks), a medium-term rise (292.65% over three months), and a longer-term gain (116.93% over one year), with expected trading ranges indicating moderate volatility.